Warning: The NCBI web site requires JavaScript to function. more...
Division of Rheumatology, University of California, San Francisco, San Francisco, CA, USA. nelane@itsa.ucsf.edu
Osteoporosis results from a loss of bone mass and bone structure such that the bone becomes weak and fractures with very little trauma. Until recently, the approved osteoporosis therapies prevented more bone loss by altering osteoclast activity and lifespan. Recently, attention has turned away from osteoclast inhibition to agents that can stimulate the osteoblast to form new bone, or anabolic agents. This article reviews both approved and experimental anabolic agents that improve bone mass by improving osteoblast activity, or increasing osteoblast number. The use of the anabolic agents to improve bone mass and strength followed by agents that prevent the new bone mass from being lost may offer the ability to cure osteoporosis and reduce bone fracture healing time.
Images from this publication.See all images (1) Free text
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on